Comparing two knee steroid injections and their effect on blood sugar in diabetes
Compares two steroid knee injections for knee arthritis in adults with type 2 diabetes.
Key facts
- Who runs it
- University of Kansas Medical Center
- Where
- Kansas City, United StatesSee the site
- Trial code
- Registry title
- Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 120 people, planned
- Started
- 16 Aug 2024
- Expected to end
- 16 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- triamcinolone acetonide extended-release injectable suspension; TCA-ER
- Triamcinolone Acetonide- Immediate Release;TCA-IR
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with knee osteoarthritis and type 2 diabetes who do not use insulin. It compares two knee injections and their effect on blood sugar.
- Age
- 40 years or older
- Sex
- Men and women can join
- Disease stage
- Painful knee osteoarthritis for at least 6 months, Kellgren-Lawrence Grade 2-4. Type 2 diabetes for at least 1 year, HbA1c 6.5-9% (48–75 mmol/mol), kidney function (eGFR) at least 50 mL/min/1.73 m2.
- Earlier treatment
- Stable doses of diabetes medicines other than insulin for at least 1 month. No steroid injection in any joint within 3 months, and no hyaluronic acid injection in the knee within 6 months.
- Biomarker or test result
- HbA1c 6.5-9% (48–75 mmol/mol) and triglycerides under 500 mg/dL (5.6 mmol/L), both measured in the past 8 weeks. Willing to wear a continuous glucose monitor all day.
Main reasons for not taking part
- Other types of arthritis, such as rheumatoid arthritis
- Infection in the knee, or metal hardware in the knee
- Moderate or severe kidney, liver or thyroid disease
- Known HIV, hepatitis B or hepatitis C infection
- Allergy to triamcinolone, or active cancer
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- 1. Written consent to participate in the study. 2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions; Male or female ≥40 years of age. 4. Females with negative pregnancy test, who are not breastfeeding and have no intention to become pregnant during the time from screening through EOS; Type 2 DM for at least 1 year prior to Screening. 6. Currently being treated with injectable (except insulin) and/or oral antidiabetic agents with stable doses for at least 1 month prior to Screening; HbA1c 6.5-9% (in past 8 weeks). 8. Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73 m2. (in past 8 weeks) 9. Triglycerides <500 mg/dL (in past 8 weeks) 10. Painful symptoms associated with OA of the knee for ≥6 months prior to Screening (NRS of 4-9 during most of the 30 days prior to enrollment); Currently meets modified ACR criteria (clinical and radiological) for OA (Altman et al, 1986) as follows:; Knee pain; At least 1 of the following:; Stiffness <30 minutes; Crepitus; Osteophytes 12. Index knee pain more than 15 days over the last month (as reported by the subject); Kellgren-Lawrence Grade 2-4. 14. Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the required time during the study and comply to the correct use requirements of CGM throughout the trial and perform self BG checks as directed; Adequate BG data collected during the pretreatment phase (Day -10 through Day -1) ≥70% data available
Who cannot take part
- Presence of surgical hardware or other foreign body in the index knee
- Active cancer. Previous or Concomitant Treatment-related Criteria
- IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening
- IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening
- Oral corticosteroids (investigational or marketed) within 1 month of Screening
- Inhaled, intranasal, or topical corticosteroids (investigational or marketed) within 2 weeks of Screening
- Any other IA investigational device, drug/biologic within 6 months of Screening or 5 half-lives (whichever is longer)
- Prior arthroscopic or open surgery of the index knee within 12 months of Screening
- Planned/anticipated surgery of the index knee or any other surgery during the study period
- Requiring or likely to require treatment with corticosteroids during the study period based on subject medical history
- Active substance abuse (drugs or alcohol), history of chronic substance abuse within the last year, or prior chronic substance abuse judged by the Investigator likely to recur during the study
- Receipt of a live or live attenuated vaccine within 3 months of Screening
- Disease-related Criteria
- Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease
- History of infection in the index knee joint
- Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening
- Moderate or severe kidney, liver, or thyroid disease
- Known hypersensitivity to any form of triamcinolone
- History of sarcoidosis or amyloidosis
- Active or history of malignancy within the last 3 years, except for resected basal cell carcinoma, squamous cell carcinoma of the skin, or effectively managed cervical carcinoma
- Known active or quiescent systemic fungal, bacterial (including tuberculosis), viral, or parasitic infections or ocular herpes simplex
- Any infection requiring IV antibiotics within 4 weeks of Screening or infection requiring oral antibiotics within 2 weeks of Screening
- History of osteomyelitis
- Known or clinically suspected infection with human immunodeficiency virus (HIV) or hepatitis B or C viruses
- History or active Cushing's or Addison's syndrome
- Any other clinically significant psychiatric acute or chronic medical conditions that, in the judgment of the Investigator, would preclude the use of an IA corticosteroid or NSAIDs or that could compromise subject safety, limit the subject's ability to complete or adhere to the study, and/or compromise the objectives of the study
- Subjects on Coumadins with INR ≥5 will be excluded (Bashir et al, 2015) Subject-related Criteria
- Unstable joint (such as a torn anterior cruciate ligament) within 12 months of Screening
- Glaucoma
- IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening
- Use of acetaminophen, or acetaminophen-containing products, from Screening through Day 14 (completion of post-treatment BG monitoring)
- Skin breakdown at the knee where the injection would take place
- Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 2 years of Screening
Where in United States
- University of Kansas Medical CenterKansas City, United StatesContact: Neil Segal, MD, MSTaking people
About the trial
What the trial wants to find out
A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected).Total study duration for individual subject will be about 4 months, which includes 3 weeks of Screening period, 10 days of pretreatment phase, treatment day, and 12 weeks of post-treatment period.
The 2 groups in the trial
- TA-ERExisting treatment, for comparison
Name: ZILRETTA (triamcinolone acetonide extended-release injectable suspension; TA-ER) Active ingredient: Extended-release formulation of TA in 75:25 poly (lactic-co-glycolic) acid (PLGA) microspheres Dosage: Nominal 32 mg TA, intra-articular (IA) injection, administered as a 5 mL injection Mode of Administration: IA Knee Injection
Treatment: triamcinolone acetonide extended-release injectable suspension; TCA-ER
- TA-IRExisting treatment, for comparison
Name: Kenalog®-40 (triamcinolone acetonide injectable suspension) Active Ingredient: Triamcinolone Acetonide- Immediate Release (TA-IR) Dosage: 40 mg/mL, IA, administered as a 1 mL Injection: TA-IR Mode of Administration: IA Knee Injection
Treatment: Triamcinolone Acetonide- Immediate Release;TCA-IR
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- RCT to Evaluate the Effects of Zilretta (Triamcinolone Acetonide- Extended Release) and Kenalog (Triamcinolone Acetonide- Immediate Release) on Blood Glucose in Subjects With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus
- Plain-language title
- Comparing two knee steroid injections and their effect on blood sugar in diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 October 2026